Ona Therapeutics develops first‑in‑class antibody‑drug conjugates (ADCs) that target novel antigens discovered from the biology of treatment‑refractory advanced cancers. By partnering with academic and clinical researchers, they identify molecular changes in resistant tumors and engineer precision ADCs with optimized pharmacokinetics and payload delivery, advancing only candidates with strong preclinical efficacy and safety.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
5OCIFounders
Product
Problem
Patients with advanced, treatment‑refractory cancer often exhaust standard therapies and are left without effective treatment options. A limited understanding of how cancers evolve after multiple lines of therapy hampers the discovery of new, actionable targets.
Solution
Ona Therapeutics focuses on creating first‑in‑class antibody‑drug conjugates (ADCs) that target novel antigens identified from the biology of refractory tumors. By partnering with academic and clinical researchers, the company isolates molecular changes that arise after standard of care treatment and selects targets beyond traditional tumor antigens. These targets are incorporated into precision‑engineered ADCs and antibody therapeutics using advanced protein‑engineering techniques to optimize pharmacokinetics and tolerability. The streamlined development pipeline advances only candidates with strong preclinical activity and safety profiles, aiming to deliver new treatment options for patients who have exhausted existing therapies.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking novel ADC candidates, as well as oncologists and clinical researchers focused on treatment‑refractory solid tumors.
Features
- Target discovery pipeline that leverages real‑world samples from refractory cancer patients to identify novel molecular targets
- Custom antibody engineering platform for optimizing binding affinity, pharmacokinetics, and payload delivery
- Precision ADC design with flexible payload options, including dual‑payload configurations
- Integrated development process that accelerates preclinical validation and IND‑enabling activities
- Partnerships with leading academic and clinical groups to access privileged biological insights